Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pluri Inc.PSTI · Entity 7728 | Director | July 15, 2021 | July 26, 2021 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | June 05, 2025 | June 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pluri Inc.
Report date July 15, 2021 · Filed July 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2021-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-07-15 · Grant · Acquired 20,000 · Balance 20,000 F1: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2: The shares vest over four years as follows: 12.5% shall vest on the 6 month anniversary of the date of grant and the remaining shares vest in 14 equal instalments every 3 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: The shares vest over four years as follows: 12.5% shall vest on the 6 month anniversary of the date of grant and the remaining shares vest in 14 equal instalments every 3 months thereafter.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,504 |
Reported balance
After 2025-06-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-06 · Exercise / conversion · Acquired 9,632 · Balance 22,504 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-06 · Exercise / conversion · Disposed 9,632 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 14,492 |
Reported balance
After 2025-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-05 · Grant · Acquired 14,492 · Balance 14,492 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.
F4: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2025 Filed Jun 9, 2025 20:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 9,632 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083765 · ownership.xml · derivative · entry 2 Shalev Varda · CIK 0001873934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F3 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 9,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-083765 · ownership.xml · nonDerivative · entry 1 Shalev Varda · CIK 0001873934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 14,492 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083765 · ownership.xml · derivative · entry 3 Shalev Varda · CIK 0001873934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,492 Underlying: Ordinary Shares · 14,492 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F4 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 02, 2024 Filed Sep 4, 2024 11:40 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 12,872 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-103113 · ownership.xml · derivative · entry 2 Shalev Varda · CIK 0001873934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on September 2, 2023 and vested on September 2, 2024. F3 · derivative.expiration_date: Restricted share units were granted on September 2, 2023 and vested on September 2, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 02, 2024 Filed Sep 4, 2024 11:40 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 12,872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-103113 · ownership.xml · nonDerivative · entry 1 Shalev Varda · CIK 0001873934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 11:53 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 9,632 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071081 · ownership.xml · derivative · entry 1 Shalev Varda · CIK 0001873934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,632 Underlying: Ordinary Shares · 9,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F2 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 02, 2023 Filed Sep 5, 2023 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 12,872 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048125 · doc4.xml · derivative · entry 1 Shalev Varda · CIK 0001873934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,872 Underlying: Ordinary Shares · 12,872 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on September 2, 2023 and vest on September 2, 2024. F2 · derivative.expiration_date: Restricted share units were granted on September 2, 2023 and vest on September 2, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 15, 2021 Filed Jul 26, 2021 20:24 UTC | Pluri Inc. PSTI · Entity 7728 | GrantRestricted Stock Units | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-038645 · ownership.xml · nonDerivative · entry 1 Shalev Varda · CIK 0001873934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · security: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · date: The shares vest over four years as follows: 12.5% shall vest on the 6 month anniversary of the date of grant and the remaining shares vest in 14 equal instalments every 3 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.